quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:15:00·36d
PRRelease
Gain Therapeutics Inc. logo

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

GANX· Gain Therapeutics Inc.
Health Care
Original source

Companies

  • GANX
    Gain Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 7UpdateScotiabank$12.00
  • Dec 6UpdateROTH MKM$7.00
  • Aug 14UpdateOppenheimer$8.00
  • Nov 3UpdateB. Riley Securities$21.00

Related

  • INSIDER28d
    SEC Form 4 filed by Mack Gene
  • INSIDER28d
    SEC Form 4 filed by Fuggetta Gianluca
  • SEC28d
    SEC Form 10-K filed by Gain Therapeutics Inc.
  • SEC28d
    Gain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR29d
    Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
  • PR35d
    Gain Therapeutics to Present at the 38th Annual ROTH Conference
  • SEC36d
    Gain Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR43d
    Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022